Whole-exome sequencing and in silico neoantigen prediction have demonstrated that a high level of CD8+ T-cells specific to MUC16 neoantigens is associated with long-term survival in patients with pancreatic cancer. Here, CD8A is linked to familial pancreatic carcinoma.